Latest & greatest articles for ropinirole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ropinirole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ropinirole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ropinirole

1. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis. (Abstract)

Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis. To evaluate the comparative efficacy and safety of ropinirole and pramipexole as adjunctive therapies to levodopa (L-dopa) for the management of advanced Parkinson's disease (PD), via a systematic review and network meta-analysis.Twenty-one double-blind randomised controlled trials of patients with advanced PD with motor fluctuations (...) receiving L-dopa comparing ropinirole or pramipexole with comparators were identified from 2550 publications. Bayesian indirect comparison methods were applied to independently review efficacy outcomes including off-time reduction, Unified Parkinson's Disease Rating Scale-Activity of Daily Living (UPDRS-ADL) and UPDRS-motor scores, and safety outcomes including adverse events (AE) and patient withdrawals, to determine indirect treatment comparison mean differences (MD) or hazard ratios (HR) with 95

2020 Advances in therapy

2. Restless legs syndrome: Ropinirole

Restless legs syndrome: Ropinirole Ropinirole | Prescribing information | Restless legs syndrome | CKS | NICE Search CKS… Menu Ropinirole Restless legs syndrome: Ropinirole Last revised in December 2016 Ropinirole What doses of ropinirole are indicated for restless legs syndrome? Initial dose : 250 micrograms 1–2 hours before bedtime (or anticipated onset of symptoms). Titration : increase if needed by 250 micrograms after 4-7 days. Maximum recommended dose : 4 mg daily. [ ; ] What (...) are the contraindications for ropinirole? Do not prescribe ropinirole for secondary restless legs syndrome , for example, caused by renal failure, iron deficiency anaemia or pregnancy. Do not prescribe ropinirole for restless legs syndrome to : Pregnant or breastfeeding women. People with hypersensitivity to ropinirole or to any constituent in the tablet. People with severe renal or hepatic impairment. People with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose

2020 NICE Clinical Knowledge Summaries

3. ropinirole (Requip XL)

ropinirole (Requip XL) ropinirole (Requip XL®) - All Wales Medicines Strategy Group Opens in new window Cymraeg Search Search Cymraeg Menu Search › › › ropinirole (Requip XL®) Following a full submission AWMSG advice Status: Recommended Ropinirole prolonged-release (Requip XL®) is recommended for use within NHS Wales for the treatment of idiopathic Parkinson’s disease in patients already taking ropinirole immediate-release tablets (Requip®) and in whom adequate symptomatic control has been (...) established. Substitution of ropinirole prolonged-release tablets for ropinirole immediate-release may be used as: (i) Monotherapy, alone (without levodopa) in idiopathic Parkinson’s disease. (ii) Adjunctive therapy in addition to levodopa to control ‘on-off’ fluctuations which might permit a reduction in the total daily dose of levodopa. In order to limit errors, prolonged-release ropinirole should be prescribed by brand as Requip XL®. AWMSG is of the opinion that prolonged-release ropinirole (Requip XL®

2019 All Wales Medicines Strategy Group

4. Ropinirole

Ropinirole Top results for ropinirole - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ropinirole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

5. Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-Analysis. (Abstract)

Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-Analysis. Nausea and vomiting are commonly associated with medication use. Dopaminergic agonists have been associated with these symptoms, but their impact in patients without Parkinson's disease, such as those with restless legs syndrome (RLS), is not well characterized.We sought to determine whether the non-ergoline dopamine agonist ropinirole is associated with nausea and vomiting in adults with RLS.We (...) conducted a systematic review using PUBMED, EMBASE, and clinical trial databases to identify placebo-controlled clinical trials of ropinirole for RLS treatment. We extracted data including dosing schedule and the proportion of patients reporting nausea and/or vomiting. We also determined hazard ratios (HR) using a random effects proportional hazard model.We extracted data from a pool of 13 studies. The prevalence of nausea in the ropinirole-treated RLS group (RLS-R; N = 1528) was 37.2% compared to 9.4

2018 Digestive diseases and sciences

6. A Retrospective, Pooled Suicidality Evaluation of Ropinirole Immediate Release and Controlled Release for the Treatment of Restless Legs Syndrome. (Abstract)

A Retrospective, Pooled Suicidality Evaluation of Ropinirole Immediate Release and Controlled Release for the Treatment of Restless Legs Syndrome. Based on an internal request, GlaxoSmithKline conducted a retrospective pooled analysis of randomized controlled trials to compare suicidality in adult subjects with restless legs syndrome (RLS) who were being treated with ropinirole. The objective was to proactively evaluate the incidence of potentially suicidal thoughts or behaviors (suicidality (...) ) among patients with RLS treated with ropinirole immediate release (IR) or controlled release (CR).The US Food and Drug Administration approved methods previously used for the retrospective analysis of suicidality with antidepressants and anticonvulsants. Potential cases of suicidal thoughts and behavior were identified from searches of treatment-emergent adverse event preferred and verbatim terms; a review of serious adverse events; and searches of a priori-identified free text comment fields

2015 Clinical therapeutics

7. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

8. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. (Abstract)

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Dopamine agonists have a well established role in the treatment of Parkinson's disease. The choice of a particular dopamine agonist requires assessing the benefit-risk balance of each available medication.The present study evaluated the tolerability and safety of ropinirole against those of other dopamine agonists (...) events was made by consensus between the investigators.Forty randomized clinical trials were included. Direct comparison of ropinirole with bromocriptine showed a lower RR of constipation for ropinirole (0.55 [95% CI 0.35, 0.89]), while the direct comparison with levodopa showed a lower RR of dyskinesia for ropinirole (0.25 [95% CI 0.09, 0.71]); no significant differences for either dyskinesia or constipation were found when a direct comparison of ropinirole and rotigotine was made. For nausea

2010 Drug safety : an international journal of medical toxicology and drug experience

9. Ropinirole prolonged-release (Requip XL®) for the treatment of idiopathic Parkinson's disease

Ropinirole prolonged-release (Requip XL®) for the treatment of idiopathic Parkinson's disease Ropinirole prolonged-release (Requip XL®) for the treatment of idiopathic Parkinson's disease Ropinirole prolonged-release (Requip XL®) for the treatment of idiopathic Parkinson's disease All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation All Wales Medicines Strategy Group (AWMSG). Ropinirole prolonged-release (Requip XL®) for the treatment of idiopathic Parkinson's disease. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 1409. 2009 Authors' conclusions Ropinirole prolonged-release (Requip XL®) is recommended for use within NHS Wales for the treatment of idiopathic Parkinson's disease in patients already

2009 Health Technology Assessment (HTA) Database.

10. Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials

Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

11. Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. (Full text)

Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. To compare the effects of ropinirole with those of placebo on sleep, as evaluated by specific domains of the Medical Outcomes Study (MOS) sleep scale, as well as the Clinical Global Impression-Improvement (CGI-I) scale, in patients with restless legs syndrome (RLS).Meta-analysis of six randomized, double-blind, placebo-controlled (...) , parallel-group trials conducted in the United States and Europe.A total of 1679 patients aged 18-79 years with primary moderate-to-severe RLS who received ropinirole (835 patients) or placebo (844 patients).A systematic review of MEDLINE (January 1980-January 2007) and clinical trial registers was performed to identify placebo-controlled trials of ropinirole that used the 12-item MOS sleep scale to assess sleep in patients with RLS. Individual patient data from both published and nonpublished trials

2009 Pharmacotherapy PubMed abstract

12. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. (Abstract)

Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. In the absence of comparative trials a meta-analysis was performed to compare the efficacy and tolerability of the non-ergot derived dopamine agonists, pramipexole and ropinirole, in restless legs syndrome (RLS).Frequentist fixed and random-effects models were pre-specified for the direct comparisons and a Bayesian approach for the indirect comparison. Efficacy outcomes (...) included the mean change from baseline in the International RLS Study Group Rating Scale (IRLS) score and the percentage of responders on the clinical global impressions - improvement scale (CGI-I). Safety outcomes included the incidence of withdrawal and adverse events.The direct meta-analysis confirmed superior efficacy for both treatments versus placebo for the IRLS (pramipexole: -5.45; 95% CI: -7.70; -3.20; ropinirole: -3.16; 95% CI: -4.26; -2.05) and the CGI-I (pramipexole: OR=2.98; 95% CI: 2.08

2008 Sleep medicine

13. [Systemic review and meta-analysis of tolerability and safety between different titration regimes of ropinirol dose in the treatment of Parkinson's disease]. (Abstract)

[Systemic review and meta-analysis of tolerability and safety between different titration regimes of ropinirol dose in the treatment of Parkinson's disease]. Ropinirole is a non-ergoline dopamine agonist, highly selective for the D2 receptor subtype D3. In order to minimize the adverse events of the dopamine agonists, the dose of these drugs should be titrated. This implies delaying the onset of the therapeutic effects several weeks. To avoid this problem, different accelerated titration (...) of them were finally discarded leaving 12 articles to be included in this review. Treatments were divided between standard and non-standard schemes and a single branch meta-analysis of the most relevant adverse events was performed.In the studies selected, ropinirole has proven to be more efficacious than placebo and more efficacious than bromocriptina. In two trials comparing the efficacy of ropinirole versus levodopa, the latter showed a better efficacy. Patients following a non-standard titration

2008 Neurología (Barcelona, Spain)

14. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome

Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

15. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis

Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis Etminan M, Gill S, Samii A CRD summary This review compared the adverse effects of pramipexole and ropinirole (...) with levodopa and placebo in the treatment of Parkinson's disease. The authors concluded that, compared with placebo, ropinirole appears to increase rates of hypotension and somnolence more than pramipexole, while pramipexole increases hallucinations more than ropinirole. These drugs were not compared directly, thus the authors' conclusions may not be reliable. Authors' objectives To compare the adverse events associated with pramipexole and ropinirole in patients with Parkinson's disease. Searching MEDLINE

2003 DARE.

16. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. (Abstract)

Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Pramipexole and ropinirole are relatively new dopamine agonists, both of which have proven efficacy in the treatment of Parkinson's disease. There is, however, uncertainty regarding differences in the adverse event profiles associated with each drug.To compare the adverse events of pramipexole and ropinirole as reported in the peer-reviewed medical literature.We (...) systematically reviewed the medical literature to identify randomised controlled trials of pramipexole and ropinirole used in the management of Parkinson's disease. Computerised databases (including Medline, Embase, the Cochrane Library, and the International Pharmaceutical Abstracts) were used to identify pertinent articles for inclusion in this study. Trials that compared the dopamine agonists to either levodopa or placebo were included.Adverse events with these drugs included dizziness, nausea

2003 Drug safety : an international journal of medical toxicology and drug experience

17. Ropinirole for levodopa-induced complications in Parkinson's disease. (Abstract)

Ropinirole for levodopa-induced complications in Parkinson's disease. Long-term levodopa therapy for Parkinson's disease is complicated by the development of motor fluctuations and abnormal involuntary movements. One approach is to add a dopamine agonist at this stage of the disease to reduce the time the patient spends immobile or off and to reduce the dose of levodopa in the hope of reducing such problems in the future.To compare the efficacy and safety of adjuvant ropinirole therapy versus (...) placebo in patients with Parkinson's disease already established on levodopa therapy and suffering from motor complications.Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with SmithKline Beecham.Randomised controlled trials of ropinirole versus placebo in patients with a clinical

2000 Cochrane

18. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. (Abstract)

Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Long-term levodopa therapy for Parkinson's disease is complicated by the development of motor fluctuations and abnormal involuntary movements. One approach is to add a dopamine agonist at this stage of the disease to reduce the time the patient spends immobile or off and to reduce the dose of levodopa in the hope of reducing such problems in the future.To compare the efficacy and safety of adjuvant (...) ropinirole therapy with bromocriptine in patients with Parkinson's disease already established on levodopa therapy and suffering from motor complications.Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with SmithKline Beecham.Randomised controlled trials of ropinirole versus

2000 Cochrane

19. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. (Abstract)

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist.In this prospective, randomized, double-blind study, we compared the safety and efficacy of the dopamine D2-receptor agonist ropinirole with that of levodopa over a period of five years in 268 patients with early (...) Parkinson's disease. If symptoms were not adequately controlled by the assigned study medication, patients could receive supplementary levodopa, administered in an open-label fashion. The primary outcome measure was the occurrence of dyskinesia.Eighty-five of the 179 patients in the ropinirole group (47 percent) and 45 of the 89 patients in the levodopa group (51 percent) completed all five years of the study. In the ropinirole group 29 of the 85 patients (34 percent) received no levodopa supplementation

2000 NEJM Controlled trial quality: predicted high